Proceedings of the 50th Hawaii International Conference on System Sciences | 2017

How Do Patients Expect Apps to Provide Drug Information?
Anton Grube, Tobias Dehling, Ali Sunyaev
Information Systems and Systems Engineering
Research Center for IS Design (ITeG)
University of Kassel, Germany
{grube, tdehling, sunyaev}@uni-kassel.de

Abstract
Patients use various sources to obtain information on pharmaceutical drugs. Mobile health care
applications (apps) providing drug information to
users are increasingly made available and of rising
importance for the health care domain. However,
apps usually offer functionality that only medical
professionals or vendors consider useful for patients,
although their considerations are not likely to meet
patient expectations. In our exploratory study, we
identify 33 features patients expect in apps for drug
information provision with interviews and empirically assess their perceived importance in an online
survey. Results indicate that patients desire personalization features for provided information but not for
the app interface. This work contributes to research
and practice by identifying and empirically ranking
drug information provision features patients find
important. We furthermore establish a foundation for
future research on effective mobile drug information
provision and provide insights for practice on development of patient-centered mobile health apps.

1. Introduction
Medical professionals should not ask what information their patients could provide to them but what
information they should provide to their patients.
Dating back to the Hippocratic Oath such behavior
seems obvious, but today more important than ever.
A brief look at the current health information systems
(IS) landscape reveals strong affection for the big
data hype. Large quantities of personal information
are merged to pseudonymized profiles that represent
average needs and demands of all patients and mask
the needs and demands of the individual patient.
In contrast, the overall health care domain is undergoing a sweeping shift from paternalism to patient-centered health care [1]. In the past, health care
was focused on generalization and the population
level. Nowadays, patient-centered health care instead
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focuses on patients’ individual needs [2]. Pharmaceutical drugs are used in health care to cure or ameliorate symptoms of an illness or a medical condition.
Lacking drug adherence, contributing to higher
treatment costs, poor health care outcomes, loss of
confidence, and higher morbidity and mortality rates,
is a core issue in health care [3, 4]. Patients can intentionally refuse or unintentionally forget to take prescribed drugs. In the latter case, active reminders can
familiarize patients with a prescribed regimen, make
them accustomed to drug taking, and help to reduce
non-adherence [5], whereas, the former case is often
caused by a lack of information on drugs [6]. Provision of information on drugs patients take or intend to
take is crucial for the success of therapy but seldom
meets patients’ needs and demands.
The rapid growth of mobile health information
technology (IT) as well as the increasing mobile network expansion spurred the development of mobile
health IS targeting patients. Ubiquitous information
access, led to a wide spectrum of mobile health IS
promoting patients’ drug adherence through drug
information provision features. For instance, online
drug information databases, acoustic reminders, or
text messages delivered through smartphone applications (apps) [7], clearly demonstrate the potential of
current technology to provide information that patients demand [5]. However, medical professionals
and vendors remain the key interest groups. Consequently, information creation and development of
mobile health IS features for patients is often based
on requirements, objectives, and expectations of
medical professionals and vendors. Patients serve
only as recipients of drug information. Little is
known on what features patients expect in mobile
health IS for drug information provision and how
patients expect these features to help them to improve
their drug adherence.
Extant research on evaluation and assessment of
smartphone health apps for drug adherence is also
often based on the expectations and demands of interest groups other than patients. Quality benchmarks
for mobile health IS features (eg, usefulness for pa-
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tients) are usually not based on patients’ but on researchers’ or medical professionals’ expectations [5,
8–10]. Hence, developers tend to tailor mobile health
IS offerings to comply with expectations of researchers and medical professionals. However, neither medical professionals’ nor researchers’ expectations of
features to be offered in mobile health IS targeting
patients are likely to match patients’ actual expectations, requirements, and demands. Consequently,
provided drug information is often not understood, of
no avail to patients, and fails to make an impact on
patients’ drug adherence.
To move forward, our research takes a step back
and investigates the main interest group’s (patients’)
expectations for features to be offered in mobile
health IS focused on drug information provision to
improve patients’ drug adherence. As an exploratory
study towards better understanding patients’ expectations for drug provision features, this paper answers
the following research questions from the patient
perspective: What features do drug information provision apps need to offer? What is the relative importance of identified features and what aspects of
drug adherence are influenced by these features?
We solicit a study sample of potential users of
mobile health IS and determine their expectations for
features to be included in mobile health IS concerned
with drug information provision. As a first phase, we
conducted single-person, semi-structured interviews
with a group of twelve potential users of drug information provision apps. The answers were summarized, structured, and grouped. For the second phase,
208 study participants were recruited with Amazon
Mechanical Turk (AMT) [11] to find out how potential users expect the features identified in the first
phase to impact their state of health, determine the
importance of each feature, and identify the drug adherence facilitators users perceive to be impacted by
the respective feature. The drug adherence facilitators
were derived from the dimensions of a taxonomy of
health IT and drug adherence [12].
Our work contributes to the scientific knowledge
base by identifying and empirically ranking features
for mobile drug information provision health IS desired by patients. We furthermore establish a foundation for future research on effective mobile drug information provision and provide insights for practice
on development of patient-centered mobile health IS.

2. Related Research
2.1. Drug Information Provision for Patients
In the IS domain, the term ‘information’ refers to
data associated, structured, and formed to meaningful

facts [13]. ‘Information’ is used to transfer
knowledge to a recipient or a group of recipients.
Communicating information to recipients turns out
difficult because individuals’ information demands
and level of expertise vary [14]. Hence, transmitted
information often cannot be understood or is misinterpreted by individual recipients. This results in differences in understanding of communicated information for different individuals. Such differences in
understanding are particularly critical in the health
care domain (eg, for the care provider-patient communication relationship). To enhance comprehensibility of information, the same information must be
adapted to the demands and expectations of different
recipients, in order to be meaningful to all possible
recipients. Adaption can, for example, be based on
education, qualification, or demographics. Personalization based on individuals’ demands and needs is an
effective method of adapting information [15].
The relevance of information provision in today’s
health care landscape increases with the rising number of health IT solutions focusing on information
provision for patients [16, 17]. Especially usercentered health IS for patients (patient-centered
health IS) focus on tailored information provision for
patients and must be primarily guided by the demands and expectations of patients. Drug information
serves as a crucial information source for patients.
However, drug information is created by pharmaceutical companies. Patients cannot affect and are not
involved in drug information creation or its provision
process. Yet, they are the most important recipients
of drug information. This makes provision of tailored
drug information challenging.
In contrast to patients, other interest groups can
exert influence on provided information and on the
provision process itself to further their objectives.
Care providers, for instance, may be interested in
providing as little side effect information as required
by law to lower patients’ worries and uncertainties
[18]. In contrast, pharmacists are interested in comprehensive drug information provision to reduce patients' inquiries about missing information [19]. Since
patients usually do not have a medical education,
albeit carrying the sole responsibility to comply with
prescribed regimens, patients require well-crafted
drug information provision. Current drug information
provision is however inconsistent, intransparent, contradictory, and contains inappropriate wording and
technical terms [20]. Expectations for features of
different interest groups are contradictory, and more
importance is often given to medical professionals’
expectations and demands instead of the requirements of patients. Mobile health IS features for drug
information provision are often only a byproduct of
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companies’ existing health IS. However, patients’
demands need to be considered in effective mobile
health IS for patients [21].

2.2. Patient-Centered Health IT
Patient-centered health care is concerned with
care provision consistent with the values, needs, and
expectations of patients and is most beneficial when
medical professionals involve patients in health care
discussions and decisions [1, 22]. Patient-centered
health care focuses primarily on the well-being of the
individual patient instead of the financial wellbeing
of the overall healthcare industry [23]. Patientcenteredness implies that actions contributing to
health care and treatment processes can be initiated
by patients and decisions are made with patient consultation [24, 25]. Consequently, patients do not feel
disregarded and have coequal decision-making authority [26]. Patient-centered health care promises a
number of benefits for all involved interest groups
[27–29]. When patients consult online health IS, they
seek for additional information on their treatment
(eg, in case of dissatisfaction with prescribed treatment plans) and expect to find reasonable advice
helping to manage their own care [30, 31]. However,
patients usually do not have sufficient medical expertise to assess the whole picture of their state of health
and to estimate the consequences of their decisions
[32]. Hence, medical professionals still must steer
patients’ decisions and anticipate wrong decisions
through additional information provision [32, 33]. In
the end, patients and medical professionals must together shoulder the greater responsibility that comes
with the greater decision-making power of patients [34].
Patient involvement in treatment processes can
proceed in different ways [29, 35]: Patients can provide additional relevant information about their
health condition, self-quantification devices can be
employed to gather vital signs during daily life activities, or patients can share experiences with a drug or
a treatment [32]. Shared information strengthens the
decision process for medical professionals [26]. Patients’ experiences offer insights and reveal issues
often not considered during conventional medical
check-ups [36]. The enhanced information base eases
longitudinal analyses of patients’ state of health by
tracking disease courses, symptoms, and recovery
processes [25, 37]. This allows patients to recognize
potential issues and to contact medical professionals
in a timely fashion [27, 29]. Information exchange
with patients enables medical professionals to get
new insights into courses of treatment and to avoid

unforeseen pitfalls with other patients subject to similar diseases or treatment methods [38].
Patient-centered health care is a radical change in
the very traditional health care domain and has the
potential to increase patient satisfaction, quality of
care, and overall outcomes through patient empowerment [39], if patients understand the provided information and if supported by a supportive health IS
landscape [25, 37]. Health IS, tailoring provided information to patients’ demands, empower patients to
comprehend provided information.

2.3. Personalization of Drug Information
Provision
Patient-centered mobile health IS offerings bear
the potential to provide patients with tailored information. Thus, they must not be guided by one interest
groups’ demands and expectations and, in particular,
not only by medical professionals’ demands and expectations. Mobile health IS allow to offer personalization features that enhance users’ capabilities to
personalize provided information without offering
individual information for each patient. Drug information can be personalized by hiding undesired or
irrelevant information, such as pregnancy-related
information for male users, and emphasizing important information, such as pregnancy-related information for pregnant female users. In general, personalization of information in form of text may be
based on various factors, such as explicit personal
details or implicit social environmental profiling [15].
Personalization could be automated, based on manually entered preferences, or rely on general usage
patterns. In all cases, mobile health IS must offer
technical assistance for personalization because patients may not be familiar with the possibilities and
features offered by technology. Patients’ activities
must be guided, preventing them to lessen their state
of health. Instead of offering patients more degrees of
freedom for personalization, it seems more feasible to
offer a set of features that do the tailoring of information for patients and reduce their effort to personalize the desired information. This would facilitate
provision of drug information, reduce the risk of
harmful consequences, and does not require costly,
manual intervention by medical professionals.
In this research, we assess the information provision features for patient-centered mobile health IS by
consolidating patients’ expectations for drug information provision features and identifying the expected impact on patients’ state of health from the
patient perspective. Involving patients in our research
is important to determine patients’ viewpoint on features to be offered by mobile health IS for drug in-
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formation provision. The obtained catalog of desired
features can inform future research projects by eliciting patients’ perspectives and enables prioritization
of important or desired features.

3. Method
Our study is split into a qualitative interview survey and a quantitative online survey phase. To obtain
an overview of patients’ expectations for features to
be offered by mobile drug information provision
health IS, qualitative, semi-structured, single-person
interviews were conducted. Semi-structured interviews are an effective approach for requirement elicitation [40]. The result of the first phase of the study is
a consolidated list of users’ desired features for mobile drug information provision health IS and serves
as input for the second study phase. In the second
phase, users rated the features from phase one according to their importance. Furthermore, users were
asked to judge which drug adherence facilitators are
impacted by the respective feature.

3.1. Qualitative Survey Phase Design
The interviewees for the initial user survey were
aware of the domain and topic of the study. The interviews were conducted by one researcher following
an interview guide. In the beginning, the interviewer
introduced the domain of health care and explained
the concept of mobile drug information provision
health IS and how they are intended to influence drug
adherence through drug information provision. After
the introduction, demographics were collected (eg,
gender, age). In the following a scenario, where interviewees were asked to imagine themselves in a
situation searching for online drug information, was
introduced. In essence, participants were asked exactly one main question: “What features can you imagine in a web application for drug information provision?”. Interviewees were also asked to describe desired features for mobile drug information provision
health IS. Finally, all mentioned desired features
were clearly named and described, duplicates were
removed, and the features were grouped according to
emerging patterns. Interviews were coded independently by two researchers to avoid bias.

3.2. Facilitation of Drug Adherence
To find out how patients perceive the features to
impact drug adherence in the quantitative survey, we
derived six drug adherence facilitators from a taxon-

omy of health IT and medication adherence 1 [12].
The dimensions of the taxonomy indicate which drug
adherence facilitators are potentially enhanced
through health IS features. Study participants were
asked for a binary decision whether in their opinion
the drug adherence facilitators are affected by the
respective feature.
The first drug adherence facilitator is ‘Seamless
data input’. Ease of data input is crucial for users’
future behavior. If users are obliged to perform many
complex steps to import or enter personal health information in a mobile health IS, it is unlikely that
they will use the feature. Easy and intuitive to use
health IS features lead to increased usage, or usage
intention, which in turn enables mobile health IS features to influence users’ drug adherence. The second
facilitator is ‘Location- and device-independent access’, which in general refers to the ability to make
use of a mobile health IS feature independent of location or technical equipment. If users have the ability
to make use of mobile health IS features on any device, mobile health IS use will increase and drug adherence may improve. The third facilitator is ‘Collaboration with medical professionals or other users’. Collaboration between users and medical professionals or with other users is referred to: working
jointly towards a better state of health or better health
care provision. An ongoing process of sharing information with each other and the possibility to benefit
for both sides from personal experiences or frequently occurring problems leads to enhanced drug literacy
and hence to reduced error rate when taking drugs.
The fourth drug adherence facilitator is ‘Quality control by medical professionals’. Most health care tasks
involving mobile health IS can be executed by users
without the assistance of medical professionals.
However, some tasks require qualified input from
medical professionals or other experts (eg, to assess
blood values). Medical professionals have the highest
authority in health care and are trained to provide
reliable health-related information. Involving medical
professionals in the care process, enhances information provision through reliable information on
drugs (eg, if users do not know how to behave in case
of unexpected side effects). The fifth facilitator is
‘Obtaining health-related feedback’. Feedback on
health-related topics, in form of motivational messages, adjustment of a treatment plan, or treatment
progress notifications, is supported by many mobile
health IS offerings and gives users insight into their
personal state of health. User-focused feedback on
1

The original taxonomy of health IT and medication adherence
identified seven dimensions (drug adherence facilitators). However, for this study six facilitators were used since ‘information storage’ was not consistently interpreted by study participants.
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health-related issues relieves medical professionals
from common requests. The sixth drug adherence
facilitator is ‘Personalization’. Personalization of
mobile health IS is, for example, often realized
through the adjustment of font size, hiding unwanted
content (eg, text sections or functions), or reorganizing content. Personalized mobile health IS offer tailored information provision to users and reduce users’ effort for understanding the provided information
by displaying only relevant information (eg, hiding
dosage for children for childless adults).

3.3. Quantitative Survey Phase
The online survey questionnaire started with a description of the domain and a brief instruction for the
participants. Participants were asked to rate features
on five point Likert scales according to their perceived importance (1=‘not important’, 5=‘very important’) and to select one or more drug adherence
facilitators that may be positively impacted by the
respective feature. Before finishing the survey, participants were asked for demographics and given the
opportunity to make suggestions for additional features or drug adherence facilitators not addressed in
the study.
The survey was carried out in three batches at different times via the labor market Amazon Mechanical
Turk (AMT) with one day in between each batch to
avoid daytime, or worker characteristic biases. To
avoid common method biases the items were formulated in simple language, unfamiliar terms were defined, examples were provided where necessary, and
double-barreled questions were decomposed [41]. On
the first and the second day, 50 survey participants
were solicited. Survey results were reviewed after
each batch. The advantage of AMT, compared with
conventional survey designs, where participants must
be acquired on a voluntary basis, motivated with
gifts, vouchers, or payments, is that AMT offers easy
access to a high number of potential participants.
AMT is a common tool in behavioral research and
study sample, sample quality, and sample domain can
be tailored to the needs and requirements of a particular study [42]. The number of participants can flexibly be set and is usually reached in a very short period of time (1 hour for 50 participants). Extant research demonstrates that survey results with AMT
participants have high reliability, and provide higher
quality data than student or public online surveys [11,
43–45]. Participants choose the tasks they want to
perform. Payment depends on the complexity and
duration of the task and can be freely defined. In total
we paid each study participant US$1.20 for the completion of the survey. We paid participants US$1.0

for completing the survey. Furthermore, we paid an
additional US$0.20 because we solicited only experienced participants who had previously completed at
least 5,000 tasks with an approval rate of 99% to ensure high data quality [46].

4. Results
4.1. Qualitative Survey Phase
Overall twelve participants were interviewed
(6=male, 6=female) with an average age of 35 years
(min. age=20, max. age=50). In total, 90 desired features were elicited. After removal of duplicates and
features irrelevant for drug information provision (eg,
finding medical professionals, price search engine for
drugs), 33 features remained, and were classified in
four groups: ‘Information provision features’ (INFO),
‘Graphical user interface features’ (GUI), ‘Search
and sort features’ (SEARCH), and ‘Features providing additional functionality’ (FUNC) (cf. Table 1).

4.2. Quantitative Survey Phase
Overall 208 U.S. participants responded to the survey. Each worker could only participate once in the
survey. 18 participants (9%) aborted the survey, 20
(10%) were excluded because of wrong control answers, too short survey response time (under
3 minutes for a 10-minute survey), and suspicious
answer schemes (eg, same value for all features). 168
(81%) participants completed the online survey
(89=male, 79=female) with age between 20 and 64
years. 60 (36%) participants were younger than 30
years, 53 (32%) participants were between 30 and 39
years old, 36 (21%) participants were between 40 and
49 years old, 17 (10%) participants were between 50
and 59 years old, and 2 (1%) participants were over
60 years old. 87 (52%) participants had a university
degree, 55 (33%) participants had a vocational- (24;
14%), a secondary- (17; 10%), or a general- (14; 8%)
school degree, 9 (5%) had an international Baccalaureate, 8 (5%) finished school with no qualification, 6
(4%) were still in school, and 1 MBA-, 1 Associate’s, and 1 J.D. degree. Most of the participants (103;
61%) were employed, 40 (24%) were self-employed,
11 (7%) were unemployed, 7 (4%) were university
students, 2 (1%) civil servants, 2 (1%) retired, and 3
(2%) participants were on disability insurance.
Overall participants gave positive response values
on importance (mean across all features=3.80, min.
mean=2.79, max. mean=4.6, 95% confidence interval=0.06). Table 1 lists the elicited features from the
quantitative study phase, ordered by mean importance and perceived associations with drug
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

FUNC: Check drugs for adverse drug reactions.
GUI: Well-arranged presentation of drug information (eg, clear
emphasis of headings, good structure and readability).
SEARCH: Search drugs by name.
GUI: Display dosage information based on other factors than age
(eg, weight, height, vital values).

Personalization

Obtaining health
related feedback

Quality control by
medical professionals

Collaboration with
medical professionals
or users

Location- and device
independent access

Seamless data input

4.60 5.0 0.75 15 (05) 13 (05) 61 (22) 94 (33) 62 (22) 38 (13)
4.58 5.0 0.68 59 (22) 17 (06) 48 (18) 63 (24) 49 (19) 28 (11)
4.42 5.0 0.86 96 (36) 19 (07) 35 (13) 42 (16) 34 (13) 41 (15)
4.17 4.5 1.00 23 (08) 8 (03) 57 (20) 84 (29) 36 (13) 77 (27)

GUI: Simple user interface design.
4.09
INFO: Provide information whether a drug unit can be split.
4.08
GUI: Display dosage information for a drug in different units (for 4.06
example: ml, mg, g, cl, pills).
FUNC: Compare two or more drugs (eg, side-effects).
4.06
SEARCH: Search drugs by application area/medical condition. 4.04
INFO: Provide information on drugs which may be taken to
4.03
alleviate side effects.
INFO: Provide information on how to enhance the effect of a
3.98
taken drug (eg, through diet or specific behavior).
SEARCH: Filter and search for side-effects (eg, by occurrence). 3.98
INFO: Provide information if a drug can be dissolved in a fluid. 3.98
SEARCH: Filter search results by users' personal characteristics 3.96
(eg, based on age, allergies, or personal preferences).
FUNC: Provide the possibility to store drugs users are taking.
3.92
FUNC: Provide a tutorial on how to use the application.
3.91
INFO: Provide information how a drug acts in your body.
3.90
FUNC: Provide the ability to store users' personal information
3.87
(eg, age, weight, allergies).
SEARCH: Search drugs by active ingredient.
3.80
FUNC: Allow users to comment on their experiences with a drug. 3.80
INFO: Provide additional information for the technical terms or 3.76
abbreviations (eg, links to explanations, dictionaries, synonyms).
FUNC: Provide functionality to identify drugs (eg, shape, color). 3.75
INFO: Provide information on follow-up drugs (eg, after the
3.73
maximum application period of a drug exceeded).
FUNC: Provide functionality to print out selected information.
3.67
FUNC: List all other drugs with same active ingredient as cur3.64
rently displayed drugs (eg, generic drugs).
SEARCH: Search drugs by a unique local identifier (eg, NDC,
3.57
PZN, UDI).
SEARCH: Filter for requirement of prescription.
3.55
FUNC: List all other drugs for the same application area/medical
condition as currently displayed drugs.
GUI: Integrate images/pictograms to illustrate drug information.
SEARCH: Search drugs by company/manufacturer.
FUNC: Provide image of drug package.
INFO: Provide information on homespun remedies.
GUI: Customizable user interface.

STD

Rank / Feature

Median

Mean

Table 1. Desired features for drug information provision in health IS.
Importance Perceived associations with drug
adherence facilitators: n (%)

4.0 0.88 98 (32) 37 (12) 39 (13) 36 (12) 41 (13) 59 (19)
4.0 0.99 16 (06) 17 (07) 51 (21) 79 (32) 39 (16) 45 (18)
4.0 1.04 30 (11) 10 (04) 51 (19) 88 (33) 29 (11) 55 (21)
4.0 0.92 31 (12) 12 (05) 54 (22) 66 (26) 44 (18) 43 (17)
4.0 0.94 63 (25) 19 (08) 49 (19) 52 (21) 34 (13) 36 (14)
4.0 0.97 16 (06) 10 (04) 63 (23) 71 (26) 66 (24) 48 (18)
4.0 0.91 13 (05) 13 (05) 47 (20) 55 (23) 54 (23) 57 (24)
4.0 1.01 47 (16) 17 (06) 51 (17) 58 (20) 50 (17) 72 (24)
4.0 1.02 14 (06) 10 (04) 49 (21) 71 (31) 39 (17) 49 (21)
4.0 1.09 57 (19) 13 (04) 48 (16) 45 (15) 44 (14) 101 (33)
4.0
4.0
4.0
4.0

1.16
1.03
0.97
1.12

55 (19)
47 (23)
12 (05)
71 (23)

18 (06)
17 (08)
12 (05)
14 (04)

43 (15)
31 (15)
41 (18)
37 (12)

43 (15)
32 (16)
54 (23)
41 (13)

42 (15)
23 (11)
65 (28)
41 (13)

86 (30)
52 (26)
48 (21)
111 (35)

4.0 1.05 59 (25) 19 (08) 41 (18) 53 (23) 28 (12) 32 (14)
4.0 1.08 31 (10) 10 (03) 75 (24) 33 (11) 75 (24) 83 (27)
4.0 1.12 23 (11) 12 (06) 45 (21) 63 (29) 45 (21) 27 (13)
4.0 1.07 38 (19) 10 (05) 33 (16) 61 (30) 33 (16) 29 (14)
4.0 1.00 15 (06) 9 (04) 66 (28) 65 (27) 52 (22) 32 (13)
4.0 1.12 36 (18) 21 (11) 26 (13) 37 (19) 31 (16) 49 (25)
4.0 1.08 21 (09) 17 (07) 62 (27) 66 (29) 31 (14) 31 (14)
4.0 1.24 83 (33) 22 (09) 41 (16) 44 (17) 30 (12) 33 (13)
4.0 1.09 53 (21) 13 (05) 53 (21) 47 (19) 31 (12) 57 (22)

3.40 3.5 1.12 22 (10) 11 (05) 61 (29) 59 (28) 32 (15) 26 (12)
3.24
3.23
3.06
2.86
2.79

3.0
3.0
3.0
3.0
3.0

1.12
1.22
1.18
1.35
1.25

30 (16)
65 (30)
22 (14)
10 (06)
33 (13)

Average and total values: 3.80 3.9 1.94 1304
(16%)

14 (08)
20 (09)
13 (08)
10 (06)
25 (10)

24 (13)
35 (16)
19 (12)
33 (19)
25 (10)

34 (18)
46 (21)
54 (34)
27 (16)
14 (05)

32 (17)
22 (10)
17 (11)
37 (21)
21 (08)

50 (27)
28 (13)
34 (21)
56 (32)
144 (55)

502
(06%)

1494
(18%)

1777
(22%)

1309
(16%)

1757
(22%)
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adherence facilitators. Based on these results, the
derived features were classified into three groups:
‘Essential features’, ‘Nice-to-have features’, and
‘Convenience features’ (cf. Figure 1). Essential features (4 items) were rated most important for drug
information provision mobile health IS. Nice-to-have
features (23 items) represent the class of contextspecific features, that may be irrelevant for some user
groups but advantageous for other users (eg, a tutorial
on app usage may be superfluous by experienced
users but desired for unexperienced users). Convenience features (6 items) are features with the lowest
importance ratings, these features may offer useful
functionality for some users of mobile drug adherence health IS. Figure 1 shows the breakdown by
average feature rating in groups.
Most features facilitate drug adherence through
‘Quality control by medical professionals’ and ‘Personalization’ (both 22%). At the end of the study,
participants were asked to comment on the study or
to propose features, which were not elicited in the
first phase of our study. Most participants (130; 77%)
ignored the free text field or noted, that the amount of
features leaves nothing more to expect. However, 38
participants responded with detailed feedback on the
study and detailed feature descriptions for mobile
drug provision health IS. A noticeable amount of
feedback is concerned with demand for a feature establishing communication between care-providers or
pharmacists and patients. For instance, survey participants stated:
“I did feel the option to see other users’ feedback/opinions would be incredibly valuable.”
“Ability to communicate with a doctor”
“I might add some kind of functionality to allow
the user to get in contact with a pharmacist.”
We selectively address further constructive answers in the discussion section. A complete list of
participants’ feedback as well as the complete survey
results is available from the authors upon request.

5. Discussion
This study investigates features desired by users
for drug information provision through mobile health
IS. It is apparent from the qualitative survey phase
that users are mostly interested in features enabling
them to refine provided drug information and to
quickly find certain information (eg, drug information on alternative or similar drugs for the same
application area). Demand for personalization or individualization of the provided drug information is
lower. Refinement and personalization features can
both enable patients to tailor provided drug infor-

mation to their needs and demands. Previous research
discovered that provided drug information usually
exceeds the amount of information required by patients [20]. Hence, patients demand features that enable them to hide unwanted or irrelevant information
or to enrich the provided information with explanations or additional information [47].
Results of the quantitative survey phase demonstrate that features for adverse drug reaction check,
search features, and well-arranged drug information
presentation are the most desired features. This is
also supported by extant research in the domain of
clinical pharmacology [48]. Features like search
drugs by manufacturer (#30), show image of a drug
package (#31), show information on homespun remedies (#32), and customization of the graphical user
interface (#33) are the least desired features. However, these features also received high importance ratings by several survey participants (29 (17%), 21
(13%), 25 (15%), and 19 (11%) participants gave the
highest possible rating, respectively). These results
indicate that users may underestimate the riskiness of
features. Features #32 and #33 may, for example,
bear risks by providing dangerous information (eg,
ineffective homespun remedies [49]) or through accidental hiding of relevant information on drugs
through wrong personalization preferences.
When it comes to seeking health information
online, most users are motivated by an illness or a
problematic situation [50]. Users search for information helping them to make the right decisions to
solve the problem. Uncontrollable problems, in particular uncontrollable health problems attributed to
wrong drug application, may cause serious harm to
users’ state of health [4, 51]. Hence, users want to
receive the desired information, and to take action
quickly. Our survey supports these findings by a low
demand for the feature: “Customizable user interface.” (#33, mean=2.79) (cf. Table 1). Users expect
easy-to-use user interfaces without or with little setup
effort, which for instance, two participants explicitly
requested:
“Other than making it easy to find info on medications, no.”
“Just make it as easy to use as possible. […] they
[people] can be easily confused.”
Furthermore, survey participants mentioned that
they prefer information whether drugs are covered by
users’ health insurance. For instance, one survey participant stated:
„Also would it be possible (or impossible!) to
load insurance information such as co-pays, deductibles, coinsurance, etc. by insurance provid-
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Figure 1. Mean importance values for all features. (Vert.-axis: Mean importance; Hor.-axis: Feature #)
er, so that a US patient would be able to know if
they could afford to take the medicine or not? “
The quantitative survey phase reveals associated drug
adherence facilitators for each feature but also gives a
general overview of most often associated facilitators
over all features. Overall, the most influential drug
adherence facilitators for the analyzed features are:
‘Quality control by medical professionals’ (22%),
‘Personalization’ (22%), and “Collaboration with
medical professionals or users” (18%) (cf. Table 1).
Extant research supports our findings on usefulness
of social support for patients to find relevant information in social networks [52]. Since features fostering communication between medical professionals or
other users were not included in our survey, many
survey participants explicitly mentioned to consider
these features (cf. Section 4.2).
In contrast to the qualitative phase, where user interface personalization features were frequently mentioned in personal interviews, our findings from the
quantitative phase reveal the exact opposite. Users
expect personalization features only for the provided
drug information, which would result in lower effort
to obtain the demanded information. These findings
are supported by high ratings for personalization features (#4, mean=4.17; #14, mean=3.96) and by participants’ responses in the open text answer section of
the survey. For instance, two participants stated:
“A personal journal section where users can
write down their experiences […] can be helpful
to keep track of how effective certain treatments
on a personal basis. The patient could easily
track their thoughts, benefits, and side-effects of
each medication they are taking in one place
online.”
“[…] Most [features] were geared towards personalization.”
Many features, frequently mentioned in the quantitative survey and highly demanded by patients in
the quantitative study are not offered in today’s mo-

bile health IS landscape. In the qualitative survey
phase, participants often mentioned features, that
allow to check for adverse drug reactions or to compare drugs (eg, by side-effects). In the quantitative
phase, importance of these features for patients was
confirmed through high ratings (#1, mean=4.6; #8,
mean=4.06). These results indicate, that patients need
information on drug compatibility and on negative
consequences when taking specific drugs. In contrast,
mobile health IS offerings available today seem rather focus on covering many platforms to offer their
features to patients (eg, availability of apps offering
features to improve drug adherence on multiple mobile OS platforms) or the implementation of fancy
technologies (eg, cloud computing features) fostering
location and device independent access to information. In our study, the drug adherence facilitator:
“Location- and device independent access” is least
often associated with features for drug information
provision, which indicates patients’ unawareness or
lack of interest for features enabling patients to store
personal drug information in cloud services or accessing them with different devices. Furthermore,
extant research results reveal a demand for mobile
health IS offering a wide range of features and enhanced levels of functionality [9]. Our study results
reveal that patients find only a small set of features
very important. Additional features could be added to
target specific patient groups and diversify offered
mobile health IS. Offering functionality for a designated interest group or domain could meet expectations more effectively, reduces sources for errors, and
offers greater benefit for users. This would also entail
easier system design due to a smaller set of features
to develop, to test, and to maintain and purposeful
attention to specific needs of a specific group of users.
Our study provides insights on the relative importance of drug information provision features for
users but does not provide insights on other interest
groups in health care. Hence, future research should
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investigate whether and how the identified features
are important to medical professionals, pharmacists,
and vendors. Given that desired features are highly
dependent on factors such as experiences or disease
patterns, evaluating expected features under different
contextual conditions or comparing expectations of
different health care interest groups seem to be promising research directions. Furthermore, it is unclear
whether features demanded by patients, can be beneficial for patients and improve patients drug adherence. After careful elaboration and design, the efficacy of these features must be tested and established in
real world settings (eg, with a clinical trial).
Limitations of our study affect the following aspects. First, although our sample size for the qualitative phase (12 respondents) is sufficient to provide an
estimate of patients desired features, it is relatively
small. A larger sample size may include further user
groups and identify further desired features. Second,
the quantitative study is limited to one country.
Hence, a larger sample might incorporate perspectives from different countries with different health
care expectations. Third, the quantitative survey was
carried out via the labor market AMT with a participants group restricted to the U.S. Different sampling
strategies may lead to different results. Furthermore,
inclusion of international participants from other regions than the U.S., might also lead to different feature ratings and overall different survey outcomes. A
larger sample size would also allow to account for
differences in financial status and insurance situation.
A promising opportunity would be to explore users’
expectations for features for drug information provision across cultures. Fourth, our research only considers users’ expectations for features for drug information provision. We did not cover features that users’ do not want in drug information provision apps,
which might reveal different insights. Furthermore,
features appearing important in the qualitative survey
phase, turned out not important in the quantitative
study phase (eg, interface personalization), which
indicates that patients’ demands may vary due to various reasons. Features may seem important on paper
but are perceived as unimportant when implemented.
The results of our research contribute to the development of patient-centered mobile health IS. Identifying patients’ demands and preferences for mobile
health IS features and implementing these in ‘readyto-use’ mobile health IS offerings promotes patient
involvement, participation and empowerment. Design
and development of mobile health IS targeting drug
adherence in form of mobile apps based on patients’
ideas and beliefs might lead to more frequent use.
This may in turn lead to higher effectiveness of these
apps and improve health care outcomes.
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